Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Summary

The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received one or two prior chemotherapy regimens for advanced disease.

Timeline

Start

2017-08-14

Primary completion

2017-12-27

Completion

2018-01-31

Outcome

Outcome not reported

Stopped (Enrollment): “Low enrollment and lack of clinical activity in other CRS-207 studies.”

Drugs

Indications